Back to Search
Start Over
Circulating tumor cells criteria (CyCAR) versus standard RECIST criteria for treatment response assessment in metastatic colorectal cancer patients
- Source :
- Journal of Translational Medicine, Vol 16, Iss 1, Pp 1-11 (2018), Journal of Translational Medicine, Digibug. Repositorio Institucional de la Universidad de Granada, instname
- Publication Year :
- 2018
- Publisher :
- BMC, 2018.
-
Abstract
- The use of circulating tumor cells (CTCs) as indicators of treatment response in metastatic colorectal cancer (mCRC) needs to be clarified. The objective of this study is to compare the Response Evaluation Criteria in Solid Tumors (RECIST) with the Cytologic Criteria Assessing Response (CyCAR), based on the presence and phenotypic characterization of CTCs, as indicators of FOLFOX–bevacizumab treatment response. We observed a decrease of CTCs (42.8 vs. 18.2%) and VEGFR positivity (69.7% vs. 41.7%) after treatment. According to RECIST, 6.45% of the patients did not show any clinical benefit, whereas 93.55% patients showed a favorable response at 12 weeks. According to CyCAR, 29% had a non-favorable response and 71% patients did not. No significant differences were found between the response assessment by RECIST and CyCAR at 12 or 24 weeks. However, in the multivariate analysis, RECIST at 12 weeks and CyCAR at 24 weeks were independent prognostic factors for OS (HR: 0.1, 95% CI 0.02–0.58 and HR: 0.35, 95% CI 0.12–0.99 respectively). CyCAR results were comparable to RECIST in evaluating the response in mCRC and can be used as an alternative when the limitation of RECIST requires additional response analysis techniques.<br />This work was supported by Roche Spain and a Ph.D. grant from the University of Granada.
- Subjects :
- 0301 basic medicine
Oncology
Male
Multivariate analysis
Organoplatinum Compounds
Colorectal cancer
Leucovorin
lcsh:Medicine
0302 clinical medicine
Circulating tumor cell
Antineoplastic Combined Chemotherapy Protocols
Neoplasm Metastasis
CyCAR
Metastatic colorectal cancer
General Medicine
Middle Aged
Reference Standards
Neoplastic Cells, Circulating
Prognosis
Bevacizumab
Treatment Outcome
Response Evaluation Criteria in Solid Tumors
030220 oncology & carcinogenesis
Female
Fluorouracil
Colorectal Neoplasms
After treatment
medicine.drug
medicine.medical_specialty
Treatment response
Immunomagnetic separation
General Biochemistry, Genetics and Molecular Biology
03 medical and health sciences
Internal medicine
Cell Line, Tumor
medicine
Humans
Proportional Hazards Models
business.industry
Research
lcsh:R
Circulating tumor cells
medicine.disease
030104 developmental biology
Receptors, Vascular Endothelial Growth Factor
RECIST
Multivariate Analysis
business
Follow-Up Studies
Subjects
Details
- Language :
- English
- ISSN :
- 14795876
- Volume :
- 16
- Issue :
- 1
- Database :
- OpenAIRE
- Journal :
- Journal of Translational Medicine
- Accession number :
- edsair.doi.dedup.....1068f76edd73589ece55465418056b57